Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04692155
Title Phase Ib/II Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL) (CHOP U2)
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Alabama at Birmingham

mantle cell lymphoma


Cyclophosphamide + Doxorubicin + Prednisone + Ublituximab + Umbralisib + Vincristine Sulfate

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.